GDC 695
Alternative Names: GDC-695Latest Information Update: 28 Nov 2019
At a glance
- Originator Gage Development
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Actinic keratosis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for phase-I development in Actinic keratosis in USA (Topical, Gel)
- 06 Sep 2017 Gage Development completes a phase I trial in Actinic keratosis in USA (Topical) (NCT02952898)
- 31 Oct 2016 Phase-I clinical trials in Actinic keratosis in USA (Topical) in October 2016 (NCT02952898)